Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 positive||colorectal cancer||predicted - sensitive||Margetuximab + MGD013||Case Reports/Case Series||Actionable||In a Phase I trial, MGD013 and Margetuximab (MGAH22) combination treatment resulted in a partial response in a patient with ERBB2 (HER2)-positive colorectal cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD‑1 and LAG‑3, in patients with unresectable or metastatic neoplasms.||Full reference...|